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Global screeningBoth histone-acetylations and histone deacetylases have been shown to play a key role in cardiac remodeling. Re-
cently, it has become abundantly clear that many non-histone proteins are modiﬁed by post-translational lysine
acetylations and that these acetylations regulate protein activity, conformation, and binding. In the present study,
non-histone acetylated proteins associatedwith heart failurewere identiﬁed. Global screening for lysine acetylated
proteins was performed using 2-dimensional gel electrophoresis coupled with immunoblotting with a primary
monoclonal anti-acetyl-lysine antibody. Lysine acetylated proteins were compared in two rodentmodels of hyper-
tensive heart failure, the Dahl salt-sensitive (SS) and spontaneously hypertensive heart failure prone (SHHF) rats
with those in corresponding controls, i.e., the Dahl salt-resistant (SR) and W (W) rat strains, respectively. Forty-
one and 66 acetylated proteins were detected in SS and SHHF failing hearts, respectively, but either not detected
or detectedwith less abundance in corresponding control hearts. Twelve of these acetylated proteinswere common
tobothmodels of heart failure. Thesewere identiﬁed usingmatrix-assisted laser desorption/ionization timeofﬂight
(MALDI-TOF/TOF) mass spectrometry followed by Mascot Analysis and included mitochondrial enzymes: ATP
synthase, long-chain acyl-CoA dehydrogenase, creatine kinase, malate dehydrogenase, and pyruvate dehydroge-
nase. The abundance of NAD-dependent deacetylase sirtuin-3 (Sirt3), a mitochondrial deacetylase was reduced
in SS and SHHF failing hearts. This is the ﬁrst description of non-histone protein acetylations associated with
heart failure and raises the prospect that acetylations of mitochondrial proteins linked to reduced Sirt3 mediate,
in part, metabolic changes in heart failure.
© 2011 Published by Elsevier B.V.1. Introduction
Histone protein acetylations, which stimulate gene expression by
destabilizing the histone–histone and histone–DNA interactions that
limit access of transcription factors toDNA, regulate cardiac remodeling.
Both class 1 and class 2 histone deacetylases (HDACs) have been closely
linked to cardiac hypertrophy [13]. Class 1 HDACs play a pro-
hypertrophic role in the heart via the suppression of anti-
hypertrophic pathways. Cardiac over-expression of HDAC2 induces hy-
pertrophy by regulating the PI3K-Akt-Gsk3β growth control pathway
[27]. Class 2 HDACs, on the other hand, prevent cardiac hypertrophy
by repressing the activity of several pro-hypertrophic transcription fac-
tors such as serum response factor (SRF), GATA4, nuclear factor of acti-
vated T-cells (NFAT), and myocardin [1]. HDAC inhibitors (HDACis) are
emerging as a therapeutic potential for cardiac hypertrophy and failure.glyceraldehyde 3-phosphate
DACs, histone deacetylases;
ain acyl-CoA dehydrogenase;
ft ventricular posterior wall
taneously hypertensive heart
SS, Dahl salt-sensitive; W, W.
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sevier B.V.Treatment with pan-HDACis can effectively halt, or even reverse, the
disease process [5]. Histone acetyltransferases (HATs), speciﬁcally
p300, have also been shown tomediate agonist-induced cardiac hyper-
trophy [7] and act as an adaptor for hypertrophy-responsive transcrip-
tion factors, including GATA4, SRF, and myocyte enhancer factor 2
(MEF2) [1].
It has been increasingly recognized that post-translational lysine
acetylation of non-histone proteins may also play an important role in
cellular signaling [24] and hundreds of non-histone proteins modiﬁed
by acetylation have been identiﬁed [6]. These lysine acetylated proteins
participate in a range of processes including transcription, cytoskeleton
dynamics, DNA repair and replication, metabolism, apoptosis, and nu-
clear transport. Furthermore, more than 20% of mitochondrial proteins
controlling cellular metabolism have been reported to undergo lysine
acetylation [15]. Non-histone protein acetylations regulate enzyme activ-
ity, e.g., in p300, ATM, PTEN, and ACS; protein–protein interactions, e.g.,
in STAT3, AR, EKLF, Importin A, STAT1, and actin; and protein stability,
e.g., in p53, Smad7, c-Myc, Runx3, H2A.z, E2F1, GATA1, HIF-1α and
SV40 T-Ag [24].
The present study was performed to determine if there are charac-
teristic non-histone acetylated proteins associated with cardiac failure.
In order to accomplish this, acetylated proteins in two different rodent
models of pressure-overload cardiac remodeling were proﬁled and
ones common to both models identiﬁed.
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2.1. Animals
Dahl salt-resistant (SR) and Dahl salt-sensitive (SS) rats were
obtained from Harlan Laboratories (Indianapolis, IN). W (W) and
spontaneously hypertensive heart failure prone (SHHF) rats were
obtained from Charles River (Wilmington, MA). SR and SS rats were
placed on a high salt ad lib diet of 8% NaCl Harlan Teklad rat chow
at 8 weeks of age. W and SHHF rats were maintained on a normal
rat chow diet. Cardiac size and function were monitored by echocar-
diography and the SR and SS rats were euthanized under anesthesia
at 29 weeks and the W and SHHF rats at 18 months.
2.2. Echocardiography
Rats were anesthetized with 3% isoﬂurane prior to echocardiogra-
phy. Transthoracic 2D-targeted M-mode and pulsed Doppler echocar-
diography (ECHO) were performed with a 15-MHz linear array
transducer (Acuson Sequoia C256 system). M-mode images of the
left ventricle were obtained from the parasternal short axis view at
the level of the papillary muscles. Left ventricular posterior wall thick-
ness (LV PWT) and left ventricular internal dimensions at the end of di-
astole (EDD) and systole (ESD)weremeasured by the American Society
of Echocardiography leading-edge method on the M-mode tracings.
Left ventricular ejection fraction (LV EF) was calculated as follows: EF
(%)=(EDD3−ESD3)/EDD3∗100%.
2.3. Protein preparation from tissue
Flash frozen tissues (left ventricular free wall+septum) were
rinsed with PBS washing buffer three times to remove contaminated
blood. For 1D western blots, 350 μl of Protein Lysis Buffer (50 mM
Tris–HCl (pH 7.4), 150 mM NaCl, 1 mM EDTA, 0.25% sodium deoxy-
cholate, 1% Nonidet P-40) containing 1× protease inhibitor cocktail
set III (CalBiochem) and phosphatase inhibitor cocktail A (Santa
Cruz Biotechnology) was added to approximately 30 mg of sample
tissue. For 2D western blots, 200 μl of 2D Lysis Buffer (30 mM Tris–
HCl, pH 8.8, 7 M urea, 2 M thiourea, and 4% CHAPS) containing 1×
protease inhibitor cocktail set III (CalBiochem) and phosphatase in-
hibitor cocktail A (Santa Cruz Biotechnology) was added to a
2 mm×2 mm×2 mm tissue sample. The tissue samples were sonicat-
ed at 4 °C, incubated on a shaker for 30 min at room temperature, and
spun at 4 °C for 30 min (12,000 rpm). The supernatant was collected
and protein concentration determined using the Bio-Rad protein
assay. Protein samples were diluted with the appropriate buffer to
equal concentrations between 5 and 8 mg/ml.
2.4. Acetyl-lysine enrichment
Left ventricular protein extracts (100 μg) over diluted in 750 μl of
Protein Lysis Buffer. Twenty microliters of protein A/G plus agarose
beads (Santa Cruz Biotechnology) were added to the sample followed
by incubation on a rotator for 1 h at 4 °C to remove any non-speciﬁc
binding of protein to the beads. The sample was then spun for
1 min at 1600 rpm and the supernatant transferred to a new tube.
Ten microliters of rabbit monoclonal anti-acetyl-lysine antibody
(Cell Signaling) was added and the mixture incubated on a rotator
at 4 °C overnight. The next day, 50 μl of protein A/G plus agarose
beads (Santa Cruz) was added to the sample followed by incubation
on a rotator for 2 h at 4 °C. The sample was then spun at 1600 rpm
for 1 min and the supernatant removed. The remaining beads were
washed three times with 1 ml of PBS containing decreasing
amounts (1%, 0.5%, and 0.05%) of Triton-X100. The protein was
then eluted from the beads by adding 2D Sample Buffer (8 M
urea, 4% CHAPS, 20 mg/ml DTT, 2% pharmalytes pH range 3 to 10(GE Healthcare), and trace amounts of bromophenol blue). The
samples were spun at 1600 rpm for 1 min and the supernatant
harvested.2.5. Detection of lysine acetylated proteins by 2D western blot
One microliter of diluted CyDye (1 nmol/μl stock diluted 1:5
with dimethylformamide) (GE Healthcare) was added to 100 μg of
protein. The samples were vortexed and then incubated for
30 min on ice, under dark conditions. One microliter of 10 mM Ly-
sine was added to each sample. The samples were vortexed and in-
cubated for an additional 15 min on ice. 2D Sample Buffer, 100 μl of
destreak solution (GE Healthcare), and Rehydration buffer (7 M
urea, 2 M thiourea, 4% CHAPS, 20 mg/ml DTT, 1% pharmalytes, and
trace amounts of bromophenol blue) added to reach a total volume
of 250 μl. The samples were mixed, spun, and equal amounts of pro-
tein loaded onto 13 cm IPG strips (pH 3–10 linear) (GE Healthcare)
under 1 ml mineral oil. IEF was performed for 12 h at 20 °C with
50 μA/strip. The focused IPG strips were incubated in freshly made
Equilibration Buffer 1 (50 mM Tris–HCl, pH 8.8, containing 6 M
urea, 30% glycerol, 2% SDS, 10 mg/ml DTT and trace amounts of bro-
mophenol blue) for 15 min with slow shaking. The strips were
rinsed with Equilibration Buffer 2 (50 mM Tris–HCl, pH 8.8, con-
taining 6 M urea, 30% glycerol, 2% SDS, 45 mg/ml iodoacetamide,
and trace amounts of bromophenol blue) and incubated for
10 min with slow shaking. The IPG strips were rinsed once in SDS-
gel running buffer, loaded into the 12% SDS-gels, and sealed with
0.5% w/v agarose solution (in SDS-gel running buffer). Paired sam-
ples were run simultaneously at 15 °C until the dye front ran out
of the gels. Gels were scanned immediately following SDS-PAGE
using Typhoon TRIO (Amersham Biosciences) following the proto-
cols provided. The scanned images were analyzed using Image
QuantTL software (GE Healthcare).
Proteins were transferred to PVDF membrane using a semidry
transfer unit. The membranes were blocked with Blocking Buffer
(5% w/v BSA in 1× TBST) for 3 h and then incubated with primary
rabbit monoclonal anti-acetyl-lysine antibody (1 μg/ml in Blocking
Buffer) (Cell Signaling) for 3 h. The membranes were then washed 3
times with TBST, incubated with CF647-labeled goat anti-rabbit IgG
secondary antibody (diluted 1:1000) (Biotium Inc.) for 2 h, and
then washed 5 times with TBST. Membranes were scanned using Ty-
phoon TRIO and image overlays were done using Image QuantTL
software.2.6. MALDI-TOF/TOF mass spectrometry
Protein spots chosen for analysis were excised by Ettan Spot Picker
(GE Healthcare) and washed multiple times to remove staining dye
and other inhibitory chemicals. Gel spots were dried and then rehy-
drated in digestion buffer containing sequencing grade modiﬁed
trypsin. Proteins were digested in-gel at 37 °C and digested peptides
extracted from the gel with TFA extraction buffer. The digested tryptic
peptides were desalted using C-18 Zip-tips (Millipore) and then
mixed with CHCA matrix (alpha-cyano-4-hydroxycinnamic acid)
and spotted into the wells of a MALDI plate. Mass spectra (MS) of
the peptides in each sample were obtained using an Applied Biosys-
tems Proteomics Analyzer and ﬁve of the most abundant peptides in
each sample were further subjected to fragmentation and tandem
mass spectrometry (MS/MS) analysis. The combined MS and MS/MS
spectra were submitted for database search using GPS Explorer soft-
ware equipped with the MASCOT search engine to identify proteins
from the NCBI non-redundant mammalian protein database. Proteins
that were identiﬁed with a conﬁdence interval (C.I.) greater than 99%
were reported.
609J.M. Grillon et al. / Biochimica et Biophysica Acta 1822 (2012) 607–6142.7. Sirt3 protein expression and 1D western blot to identify protein
acetylations
Protein (50 μg) from left ventricular tissue extracts was boiled for
5 min in Laemmli buffer and subjected to SDS-PAGE using a 10% gel.
The proteins were transferred to a PVDF membrane and washed 3
times with Tris-buffered saline containing Tween 20 (TBST) solution
(20 mM Tris, 500 mM NaCl, and 0.1% Tween-20 [pH 7.5]). The mem-
brane was then blocked in TBST containing 5% w/v non-fat dry milk
for 1 h on a shaker at room temperature. After 3 washes in TBST,
the membrane was incubated overnight at 4 °C on a shaker with ei-
ther Sirt3 rabbit monoclonal antibody (Cell Signaling) or anti-
acetylated lysine monoclonal antibody (Cell signaling) in TBST con-
taining 5% w/v bovine serum albumin (BSA) at a dilution of 1:500.
The membrane was then washed 3 times in TBST and incubated for
2 h with peroxidase conjugated goat anti-rabbit IgG secondary anti-
body (Santa Cruz Biotechnology) at a dilution of 1:2000 in TBST con-
taining 5% w/v non-fat dry milk. After 4 additional washes in TBST,
the membrane was incubated for 1 min with Amersham ECL Western
blotting detection reagent (GE Healthcare) and developed using the
Kodak Image Station 4000R Pro for varying times to obtain desirable
band intensity within a linear range and optimal saturation. The
bands were quantiﬁed by ImageJ analysis and band densities were
normalized to GAPDH.
2.8. Validation of proteins with increased acetylations by
immunoprecipitation
The left ventricular protein extracts from W and SHHF rats were
immunoprecipitated with anti-acetylated lysine monoclonal anti-
body (Cell Signaling) and subjected to Western blotting with anti-
bodies against ATP synthase β, long chain acyl-CoA dehydrogenase
(LCAD), aspartate aminotransferase (AAT), and sarcomeric creatine
kinase (sMtCK) (Santa Cruz Biotechnology).
2.9. Statistical analysis
Student's t-test for two samples assuming unequal variancewas used
to determine statistical signiﬁcance between groups. The two-tail
P-value is reported for each analysis and P-values of less than 0.05
were considered statistically signiﬁcant. Outliers (>2 SD from mean)
were dropped.
3. Results
3.1. Cardiac measurements (Table 1)
Echocardiography was performed on a weekly interval. The SS and
SHHF rats were sacriﬁced upon reaching heart failure at 29 weeks and
18 months, respectively, consistent with previous reports [9,11].
Upon sacriﬁce, the rats in failure exhibited a signiﬁcant decrease inTable 1
Cardiac parameters. The cardiac parameters for the SS and SHHF rats are shown along
with the parameters for their respective control groups, SR and W. n=4 for each
model. Left ventricular posterior wall thickness (LV PWT) and left ventricular ejection
fraction (LV EF) are represented as the average for each group±the standard
deviation.
Heart n Mean LV PWT±Std. Dev. (mm) Mean LV EF±Std. Dev. (%)
Failure — SS 4 1.718±0.162 34.96±2.57⁎
Control — SR 4 1.606±0.313 59.48±2.90
Failure — SHHF 4 1.806±0.133 42.78±7.27⁎
Control — W 4 1.822±0.170 66.39±5.74
⁎ Pb0.05 for SS vs. SR and SHHF vs. W.ejection fraction compared to controls (Pb0.05) (Table 1). Furthermore,
the SHHF rats exhibited dyspnea and upon sacriﬁce hadmarked pleural
effusion indicative of cardiac failure.
3.2. Lysine acetylated proteins in heart failure
Whole protein extracts from the left ventricle and septumof the rats
were subjected to 2D gel electrophoresis followed by immunoblotting
with an anti-acetyl-lysine antibody (Figs. 1 and 2). Forty-one and 66
acetylated protein spots were detected by immunoblotting in SS and
SHHF failing hearts that weremore abundant in the respective controls.
Total protein from each spot was also detected by CyDye labeling. Five
protein spots demonstrated increased lysine acetylation in the control
models compared to their respective heart failure models. These
spots, however, were not consistent across the two control models
and thuswere not investigated further. Twelve of the acetylated protein
spots in heart failure were common to both models.
These were identiﬁed from the SS gel using MALDI-TOF/TOF mass
spectrometry coupled to Mascot Analysis (Table 2). The identity of
each protein spot was determined with a conﬁdence interval greater
than 99%. To conﬁrm that the common spots in the SHHF gel corre-
sponded to the same proteins identiﬁed in the SS gel, two of these
common spots were excised from the SHHF gel and correctly identi-
ﬁed as mitochondrial malate dehydrogenase (peptide count: 16; pro-
tein score: 651; C.I.: 100%; sequence coverage: 59.17%) and pyruvate
dehydrogenase (lipoamide) beta (peptide count: 16; protein score:
585; C.I.: 100%; sequence coverage: 67.13%).
3.3. Conﬁrmation of increased acetylation of proteins in failure
models(Figs. 3 and 4)
To conﬁrm and complement the results of 2D Western blot, 1D
Western blot on heart extracts of W and SHHF rats was performed
with anti-acetyl-lysine antibody. Increased acetylation of proteins
was detected in SHHF compared to its control counterpart W rats
(Fig. 3).
To conﬁrm that our technique was reliably identifying proteins
with lysine acetylations in heart failure, we subjected left ventricular
tissue extracts from the SHHF failing heart to an acetyl-lysine enrich-
ment followed by 2D gel electrophoresis (Fig. 4). Five protein spots
which we believed corresponded to the lysine acetylated proteins
present in both models of heart failure were excised from the gel
and subjected to MALDI-TOF/TOF mass spectrometry. They were
identiﬁed (C.I. >99%) as ATP synthase, long chain acyl-CoA dehydro-
genase, aspartate aminotransferase, muscle creatine kinase, and sar-
comeric creatine kinase (Table 3), thus conﬁrming the speciﬁcity of
our global screening result. Corresponding spots to 11 of the 12
(PDH, spot 42, was detected in the non-enriched sample only) identi-
ﬁed ones (Section 3.2 and Fig. 2) were also present in the acetyl-
lysine enrichment gels (Fig. 4), indicating that these were speciﬁc.
3.4. Validation of hyper-acetylated proteins identiﬁed by MALDI-TOF/TOF
(Fig. 5)
The hyper-acetylated proteins that were identiﬁed by MALDI-TOF/
TOFwere validated by immunoprecipitationwith anti-acetyl-lysine an-
tibody followed byWestern blotting with antibodies against respective
proteins (Fig. 5). Increased acetylations of ATP synthase β, long chain
acyl-CoA dehydrogenase (LCAD), aspartate aminotransferase (AAT),
and sarcomeric creatine kinase (sMtCK) were observed in heart failure
(SHHF) rats compared to those of control groups (Fig. 5).
3.5. Sirt3 abundance (Fig. 6)
Since the majority of acetylated proteins identiﬁed were mito-
chondrial, the abundance of the mitochondrial deacetylase Sirt3 was
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Fig. 1. 2D western blots to identify lysine acetylated proteins in whole tissue extracts from SS failing and SR control hearts. Panel A: 2D gels (100 μg of protein extract was loaded on
each gel) from SR control (left gel) and SS heart failure (right gel) immunoblotted with anti-acetyl-lysine antibody are shown. Forty-one spots (circled and numbered in white on
the right gel) were more intense in the heart failure model while ﬁve spots (circled and lettered on the left gel) were more intense in the control model. Panel B: The 2D gels from
Panel A are depicted along with a representation of all resolved proteins. SR control (left gel) and SS heart failure (right gel) are shown. The red indicates proteins that reacted with
the anti-acetyl-lysine antibody. The green represents total protein from each extract obtained from CyDye labeling. The yellow indicates areas of overlap. Molecular weight (kDa)
markers are displayed on the left side of the gels and pH markers are displayed underneath each gel.
610 J.M. Grillon et al. / Biochimica et Biophysica Acta 1822 (2012) 607–614measured by western blot analysis in whole tissue extracts from fail-
ing SS and SHHF hearts as well as control SR and W hearts. The Sirt3
levels, normalized to GAPDH, were lower in SS and SHHF failure rats
compared to their counterparts SR and W rats (Fig. 6; Pb0.05).3.6. Acetylation of LCAD, a Sirt3 target, is increased in failure models
To establish whether down-regulation of Sirt3 might be a poten-
tial mechanism for increased acetylation of proteins in SHHF rats
compared to W rats we evaluated the acetylation status of a known
Sirt3 target LCAD [2,10]. LCAD is more acetylated in heart failure
models compared to controls (Fig. 5 LCAD).4. Discussion
Using a global screening strategy, twelve non-histone lysine acety-
lated proteins were identiﬁed that are more abundant in failing than
normal hearts. To our knowledge, this is the ﬁrst instance where in-
creased lysine acetylation of non-histone proteins has been shown in
two models of pressure-overload induced heart failure. The acetylated
proteins include multiple mitochondrial enzymes involved in all as-
pects of cardiac energy metabolism, such as pyruvate dehydrogenase,
3-oxoacid CoA transferase, NADH dehydrogenase, ATP synthase,
ubiquinol-cytochrome c reductase, long-chain acyl-CoA dehydrogenase
(LCAD), mitochondrial creatine kinase (mCK), and mitochondrial ma-
late dehydrogenase (mMDH).
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Fig. 2. 2D western blots to identify lysine acetylated proteins in whole tissue extracts from SHHF failing andW control hearts. Panel A: 2D gels (100 μg of protein extract is loaded on
each gel) fromW control (left gel) and SHHF heart failure (right gel) immunoblotted with anti-acetyl-lysine antibody are shown. Sixty-six spots (circled and numbered in white on
the right gel) were more intense in the heart failure model while ﬁve spots (circled and lettered on the left gel) were more intense in the control model. Panel B: The 2D gels from
Panel A are depicted along with a representation of all resolved proteins. W control (left gel) and SHHF heart failure (right gel) are shown. The red indicates proteins that reacted
with the anti-acetyl-lysine antibody. The green represents total protein from each extract obtained from CyDye labeling. The yellow indicates areas of overlap. Molecular weight
(kDa) markers are displayed on the left side of the gels and pH markers are displayed underneath each gel.
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noblotting of 2D gels. Possible mechanisms for changes in abundance in-
clude parallel changes in total protein expression and/or degree of
acetylation. Since lysine acetylations shift isoelectric points to the more
acidic side, the non-acetylated forms are not expected at the same spot
as the acetylated protein. Multiple spots on the 2D gel may exist for a
given proteinwith various degrees of acetylation. The possibility that cor-
responding spots represent the same proteinwith different, but the same
total amount of lysines acetylated, cannot be excluded.
MDH has lysine acetylations on four residues, Lys 185, 301, 307
and 314. Inhibition of deacetylase activity, via treatment with trichos-
tatin A and nicotinamide, increased activity of both endogenously and
ectopically expressed MDH, indicating that acetylations regulate its
enzymatic activity. MDH activity is reduced in patients with cardiacinsufﬁciency due to valvular heart disease [20], while MDH levels
were unaltered in an animal model of pressure-overload failure [4].
However, the role of MDH acetylation and its altered activity in
heart failure remains to be determined.
LCAD puriﬁed from liver mitochondria of Sirt3 knock-out mice has
been reported to be acetylated at eight lysine residues, Lys 42, 156,
189, 240, 254, 318, 322, and 358. Bugger et al. [4] showed a strong re-
duction in fatty acid oxidation without a concomitant decrease in
LCAD expression levels in pressure-overload induced failure. Acetyla-
tion of LCAD has been reported to reduce its enzymatic activity.
[10,23]. These reports coupled to our ﬁnding of increased acetylation
of LCAD raise the prospect that reduced LCAD activity, due to acetyla-
tion, may be an important aspect of perturbed fatty acid oxidation in
cardiac failure. This suggests a model in which fatty acids increase
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Fig. 3. 1D western blot to evaluate increased acetylated proteins in whole cell extracts
form W and SHHF rats. Fifty micrograms of left ventricular extract is loaded on gel and
subjected to western blot using monoclonal anti-acetylated lysine antibody (Cell Sig-
naling Inc). Molecular weight (kDa) markers are displayed on the right side of the gel.
Table 2
Lysine acetylated proteins in heart failure. Proteins which demonstrated increased lysine acetylation in both the SS and SHHF model of heart failure are listed. Spot numbers marked
with an * indicate that the identity of the protein spot was determined by MALDI-TOF/TOF mass spectrometry and Mascot analysis (C.I. >99%). Pred. M.W. = Predicted Molecular
Weight (Daltons); Pred. P.I. = Predicted P.I. (pH); C.I. = Conﬁdence Interval (%); Seq. Cov. = Sequence Coverage (%).
Protein ID Accession
no.
Pred.
M.W.
Pred.
P.I.
Peptide
count
Protein
score
C.I.
%
Seq. cov.
%
Spot #
in SS
Spot #
in SHHF
Dihydrolipoamide dehydrogenase gi|38303871 54004.1 7.96 16 465 100 45 4* 16
3-Oxoacid CoA transferase 1 gi|205829936 56168.1 8.7 20 748 100 55 5* 17
NADH dehydrogenase (ubiquinone) ﬂavoprotein 1, 51 kDa gi|55741424 50698.6 8.37 23 398 100 57.11 9* 20
ATP synthase beta subunit gi|1374715 51170.6 4.92 23 658 100 66.53 12* 9
Ubiquinol-cytochrome c reductase core protein I gi|51259340 52815.4 5.57 17 565 100 44.17 14* 62
Actin, alpha 1, skeletal muscle gi|149043182 51404.2 5.91 12 479 100 37.42 16* 10
Long-chain acyl-CoA dehydrogenase gi|205145 47842.4 7.63 23 463 100 51.16 17* 26
Long-chain acyl-CoA dehydrogenase gi|205145 47842.4 7.63 22 736 100 53.02 18* 27
Muscle creatine kinase gi|6978661 42991.8 6.58 23 656 100 62.21 19* 30
Aspartate aminotransferase, cytoplasmic gi|122065118 46399.5 6.73 26 613 100 74.09 20* 63
Sarcomeric mitochondrial creatine kinase gi|57537 47443.3 8.64 21 373 100 51.79 21* 36
Malate dehydrogenase, mitochondrial gi|38648863 35660.8 8.93 16 517 100 57.4 29* 65
Malate dehydrogenase, mitochondrial gi|38648863 35660.8 8.93 18 752 100 63.91 31* 51*
Pyruvate dehydrogenase (lipoamide) beta gi|50925725 38957 6.2 16 649 100 69.36 33* 42*
612 J.M. Grillon et al. / Biochimica et Biophysica Acta 1822 (2012) 607–614acetyl-coA acid, which in turn increases LCAD acetylation, leading to re-
duced LCAD activity and mitochondrial function.
Acetylation of the amino terminus and epsilon amino group of ly-
sine of a variety of mitochondrial outer membrane proteins has been50 kDa
40 kDa
1
pH 5.0 5.5 6.0
Fig. 4. Acetyl-lysine enrichment in SHHF failing heart: Left ventricular protein extract from the
with CyDye, and then subjected to 2D gel electrophoresis. A portion of the 2D gel is shown. Fiv
failure were identiﬁed on this gel (circled and numbered inwhite). Green indicates resolved pro
left side of the gel and pH markers are displayed underneath.reported [14]. Over 1300 mitochondrial acetylated proteins were
reported by Zhao [28]. While the effect of only a few of these acetyla-
tions has been determined, there is signiﬁcant evidence that they af-
fect protein function. For example, Trichostatin A, an inhibitor of class
1 and class 2 histone deacetylases and nicotinamide (NAM), an inhib-
itor of Sirt family deacetylases, increase the activity of enoyl-CoA
hydratase/3-hydroxyacyl-CoA dehydrogenase and malate dehydro-
genase [28]. On the other hand, argininosuccinate catalytic activity
is inhibited by acetylation. It has been hypothesized that acetylation
regulates the activity of AMP-forming enzymes [25]. Acetylation of
both mitochondrial and cytosolic acetyl-CoA synthase isoforms re-
sults in loss of function [8,25]. Acetylation of hepatic carnitine
palmitoyltransferase-1 (CPT1) has been identiﬁed in fed, but not
starved mice, and postulated in increased sensitivity to malonyl-CoA
inhibition [16]. Acetylation of the three forms of the voltage-
dependent anion channel (VDAC1-3) and Long-chain acyl-CoA
synthase 1 (ACS1) has been reported, however, the effect on activity
is not known.
Acetylations of several of the proteins found in our global screen
of failing hearts have been reported (Table 4). Acetylation of crea-
tine kinase has been demonstrated in mouse organs [12]. Previous
work has focused upon post-translational phosphorylation(s) of
creatine kinase and its regulation of activity in the heart [17]. In
our study, acetylation of both the mitochondrial and cytosolic
forms of creatine kinase was associated with heart failure, however
the role that this modiﬁcation plays in the activity of the enzyme
has not been established. Acetylation of several components of
the electron transport chain, which has decreased activity in
heart failure, i.e., complex I, III, and V [3,18], was found to be asso-
ciated with heart failure in our study, raising the possibility that
acetylation of these proteins may regulate mitochondrial respira-
tion and ATP production.2 3 4
5
6.5 7.0 8.0
SHHF failing heart was immunoprecipitated with an anti-acetyl-lysine antibody, labeled
e of the proteins which demonstrated increased lysine acetylation in both models of heart
teins obtained fromCyDye labeling. Molecular weight (kDa)markers are displayed on the
Table 3
Acetyl-lysine enriched protein spots in the SHHF failing heart. Five of the 12 proteins which demonstrated increased acetylation in heart failure were identiﬁed in an acetyl-lysine
enrichment by MALDI-TOF/TOF mass spectrometry and Mascot analysis (C.I. >99%). Pred. M.W. = Predicted Molecular Weight (Daltons); Pred. P.I. = Predicted P.I. (pH); C.I. =
Conﬁdence Interval (%); Seq. Cov. = Sequence Coverage (%).
Protein ID Accession no. Pred. M.W. Pred. P.I. Peptide count Protein score C.I. % Seq. cov. % Spot #
ATP synthase beta subunit gi|1374715 51170.6 4.92 21 1270 100 67.16 1
Long-chain speciﬁc acyl-CoA dehydrogenase gi|205145 47842.4 7.63 15 276 100 34.42 2
Muscle creatine kinase gi|6978661 42991.8 6.58 14 570 100 40.16 3
Aspartate aminotransferase, cytoplasmic gi|122065118 46399.5 6.73 12 300 100 31.72 4
Sarcomeric mitochondrial creatine kinase gi|57537 47443.3 8.64 16 565 100 38.66 5
W W SHHF SHHF
LCAD
AAT
sMtCK
ATP synthase β
Fig. 5. Validation of hyper-acetylated proteins identiﬁed withMADI-TOF/TOF by western
blot analysis. Hundred micrograms of left ventricular protein extracts from W and SHHF
rats is immunoprecipitated with monoclonal anti-acetylated lysine antibody followed
by western blot analysis with antibodies against proteins indicated on left.
613J.M. Grillon et al. / Biochimica et Biophysica Acta 1822 (2012) 607–614In the present study, Sirt3 abundance was decreased in both heart
failure models. Reduced expression of mitochondrial Sirt3 has been
shown in two models of pressure-overload induced cardiac hypertro-
phy and linked to the hypertrophic response to pressure-overload by
Gupta et al. in a series of experiments in which it was shown that28 kDa 
37 kDa
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Fig. 6. Sirt3 abundance in heart failure. Fifty micrograms of left ventricular protein extracts from hearts was subjected to 1D SDS-PAGE and then immunoblotted with monoclona
anti-Sirt3 antibody. Upper panel: representative western blot for short form of Sirt3 (28 kDa) and GAPDH. Lower panel: The abundance of short form of Sirt3, normalized to GAPDH
for failing SHHF and control W rat hearts (left) and failing SS and control SR rats (right). n=3 for each rat model. *Pb0.05 **P=0.07.Sirt3 plays an anti-hypertrophic role through LKB1-AMPK and fork-
head box O3a-dependent signaling pathways [21,26]. Sirt3 has also
been shown to regulate mitochondrial proteins through deacetyla-
tion. The activity of manganese superoxide dismutase, the primary
mitochondrial reactive oxygen species scavenger, is increased by
Sirt3-mediated deacetylation [19]. Acetyl-CoA synthetase 2 is also ac-
tivated by Sirt3 mediated deacetylation at Lysine 642 [23]. The pre-
sent results raise the prospect that a potential mechanism for
increased mitochondrial protein acetylations in heart failure is a re-
duction in the mitochondrial deacetylase Sirt3.Role of funding source
The present study was supported by Veterans Administration
Merit Award (RSD), NIH R21HL096031 (RSD), NIH KO1 DK071641
(KK), and NIH T32 HL 07692 (KRJ).Acknowledgements
We appreciate the helpful discussions with Drs. Subhash Pandey
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Table 4
Previous reports of lysine acetylations for the acetylated proteins associated with heart failure. The lysine acetylated proteins common to both models of heart failure are listed with
any known acetylation sites previously reported in the literature and the model in which the acetylations were documented.
Protein Reported acetylation site in literature Reference Model
Dihydrolipoamide dehydrogenase Lysine 127 [8] Mouse liver
NADH dehydrogenase (ubiquinone) ﬂavoprotein 1, 51 kDa Lysine 81, 104, 375 [8] Mouse liver
ATP synthase beta subunit Lysine 133, 259, 522 [8] Mouse liver
Ubiquinol-cytochrome c reductase core protein I Lysine acetylation detected but no speciﬁc site was determined [22] Mouse liver
Actin, alpha 1, skeletal muscle Lysine acetylation detected but no speciﬁc site was determined [7] Human
Long-chain acyl-CoA dehydrogenase Lysine 42 (functionally signiﬁcant), 156, 189, 240, 254, 318, 322, 358 [11] SIRT3 KO mouse liver
Muscle creatine kinase Lysine acetylation detected but no speciﬁc site was determined [13] Mouse skeletal tissue
Aspartate aminotransferase, cytoplasmic Lysine 154 [7] Human
Malate dehydrogenase Lysine 165, 185, 301, 307, 314, 329, 335 [7,8,10] Mouse liver, human
Pyruvate dehydrogenase (lipoamide) beta Lysine 354 [7] Human
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